Prostate cancer

Prodeon Medical, Inc., Announces Randomization in the Expander-2 Pivotal Clinical Trial Evaluating the Company's Investigational Treatment for Lower Urinary Tract Symptoms Associated to Benign Prostatic Hyperplasia

Retrieved on: 
Monday, September 26, 2022

BPH is a condition where the prostatic tissue grows over time and obstructs the urethral lumen, leading to LUTS.

Key Points: 
  • BPH is a condition where the prostatic tissue grows over time and obstructs the urethral lumen, leading to LUTS.
  • The interim results of the EXPANDER-1 trial were recently published in the Journal of Prostate Cancer and Prostate Diseases [The EXPANDER-1 trial: introduction of the novel Urocross Expander System for treatment of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH)].
  • Within the Expander-2 Trial, the Urocross Expander System and Retrieval Sheath will be used in a newly developed procedure called PURE (Prostatic Urethral REshaping) to relieve symptoms associated with BPH.
  • The Urocross Expander System and Urocross Retrieval Sheath are investigational devices and are not for sale in the US or outside the US.

Get Real Health Joins Client UHSFT to Highlight New Milestones for My Medical Record

Retrieved on: 
Monday, September 26, 2022

ROCKVILLE, Md., Sept. 26, 2022 /PRNewswire-PRWeb/ -- Get Real Health, a member of the CPSI (NASDAQ: CPSI) family of companies and a provider of comprehensive patient engagement tools, joins client University Hospital Southampton NHS Foundation Trust (UHSFT) in announcing the eight-year anniversary of Get Real Health's digital personal health record, My Medical Record, as well as the latest deployment of the solution at North Bristol for post-treatment follow ups for prostate cancer patients.

Key Points: 
  • My Medical Record, developed for UHSFT by Get Real Health, was introduced in 2014 as a tracker for prostate cancer patients.
  • "We have had a front row seat to the growth of My Medical Record from a pathway-specific solution to a comprehensive tool across all demographics," said Robin Wiener, President of Get Real Health.
  • "This is key in supporting a positive patient experience whilst also reducing the stress and workload for our busy clinical services."
  • The award-winning solution boasts over 130,000 users throughout the NHS, with 15 additional deployments on the horizon for 2022 and 2023.

EDAP TMS Hosting Urology Expert Panel and Live Focal One® Technology Demonstration

Retrieved on: 
Monday, September 26, 2022

LYON, France, September 26, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (the “Company”), the global leader in robotic therapeutic ultrasound, announced today it will host a urology expert panel and live Focal One® technology demonstration on September 29, 2022 at 8am Eastern Time at the Langham Hotel in New York City.

Key Points: 
  • LYON, France, September 26, 2022 -- EDAP TMS SA (Nasdaq: EDAP) (the Company), the global leader in robotic therapeutic ultrasound, announced today it will host a urology expert panel and live Focal One technology demonstration on September 29, 2022 at 8am Eastern Time at the Langham Hotel in New York City.
  • Please join the company in-person or virtually as it hosts an event featuring:
    A Focal One Robotic focal HIFU introduction from EDAP's U.S. CEO
    A live Q&A session will follow the formal presentations.
  • A recognized leader in the global therapeutic ultrasound market, EDAP TMS develops, manufactures, promotes and distributes worldwide minimally invasive medical devices for various pathologies using ultrasound technology.
  • With the addition of the ExactVu Micro-Ultrasound device, EDAP TMS is now the only company offering a complete solution from diagnostics to focal treatment of Prostate Cancer.

EQS-News: How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication

Retrieved on: 
Friday, September 23, 2022

Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States.

Key Points: 
  • Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States.
  • In fact, each year, more people die from this silent killer than from breast or prostate cancer.
  • Hyperphosphatemia (elevated phosphorus levels in the blood) is a common complication of CKD affecting over 80% of dialysis patients.
  • UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury.

Oncternal Therapeutics to Participate in the Cantor Oncology, Hematology & HemeOnc Conference

Retrieved on: 
Friday, September 23, 2022

SAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the Cantor Oncology, Hematology & HemeOnc Conference on Wednesday, September 28, 2022 at the NY Palace Hotel in New York City.

Key Points: 
  • SAN DIEGO, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Oncternal Therapeutics, Inc. (Nasdaq: ONCT), a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies, today announced that management will participate in the Cantor Oncology, Hematology & HemeOnc Conference on Wednesday, September 28, 2022 at the NY Palace Hotel in New York City.
  • Oncternal Therapeuticsis a clinical-stage biopharmaceutical company focused on the development of novel oncology therapies for the treatment of patients with cancers that have critical unmet medical need.
  • Oncternal pursues drug development targeting promising, yet untapped biological pathways implicated in cancer generation or progression, focusing on hematological malignancies and prostate cancer.
  • Oncternal is also developing ONCT-808 , an autologous chimeric antigen receptor T (CAR T) cell therapy that targets ROR1.

CLS Americas & Focalyx Present Integrated Fusion-Guided Focal Laser Ablation Solution at FOCAL 2022 Conference

Retrieved on: 
Friday, September 23, 2022

Compared to other focal therapies, focal laser ablation therapy has demonstrated higher levels of precision and accuracy with lower risk of side effects, such as erectile dysfunction and urinary incontinence.

Key Points: 
  • Compared to other focal therapies, focal laser ablation therapy has demonstrated higher levels of precision and accuracy with lower risk of side effects, such as erectile dysfunction and urinary incontinence.
  • CLS Americas is excited to demonstrate our new office-based, fusion-guided, focal Laser Ablation solution to FOCAL 2022 attendees in conjunction Focalyx Technologies and Urological Research Network, stated Michael Magnani, president of CLS Americas.
  • CLS History & Experience Image-Guided, Focal Laser Ablation of Prostate Tumors
    CLSs TRANBERG Thermal Therapy System has been used in hundreds of tumor laser ablation procedures in patients with localized prostate cancer in the US and EU using an in-bore, MRI-guided procedure.
  • CLS is leveraging its in-bore MR experience and applying it to MR/US, fusion-guided transperineal procedures and technology to perform focal laser ablation of prostate tumors with the TRANBERG Thermal Therapy System.

Clinical Practice Guidelines Recommend Genetic Testing of All Patients with Breast Cancer

Retrieved on: 
Thursday, September 22, 2022

SAN FRANCISCO, Sept. 22, 2022 /PRNewswire/ -- Invitae (NYSE: NVTA), a leading medical genetics company, released a new study in JAMA Network Open, underscoring the clinical utility of the American Society of Breast Surgeons (ASBrS) guidelines recommending universal genetic testing for patients with breast cancer, and showing universal testing improves patient outcomes. Building on a previous study reported in the Journal of Clinical Oncology, the current study is the first clinical outcomes study of a cohort of unselected patients with breast cancer who underwent universal germline genetic testing. Our data show that genetic information aids patients and their physicians in implementing effective precision treatments and personalized management for their cancer. 

Key Points: 
  • Building on a previous study reported in the Journal of Clinical Oncology , the current study is the first clinical outcomes study of a cohort of unselected patients with breast cancer who underwent universal germline genetic testing.
  • "This study and others clearly demonstrate the reason universal genetic testing for patients with breast cancer is the current standard of care in clinical practice," said Pat Whitworth, MD, lead author, breast surgical oncologist and director of the Nashville Breast Center.
  • Prior to the ASBrS guidelines, only about 25% of patients with breast cancer in the U.S. were getting genetic testing.
  • The ASBrS established guidelines recommending germline genetic testing for all patients currently or previously diagnosed with breast cancer in 2019 ( Consensus Guidelines on Genetic Testing for Hereditary Breast Cancer from the American Society of Breast Surgeons ), catalyzed and supported by our studies in the Journal of Clinical Oncology and Cancers .

New Data Published in JNCI Demonstrate Veracyte’s Decipher Prostate Genomic Classifier May Improve Identification of Aggressive Prostate Cancer in African American Men

Retrieved on: 
Thursday, September 22, 2022

(Nasdaq: VCYT) announced that data published today in the Journal of the National Cancer Institute demonstrate that the companys Decipher Prostate Genomic Classifier may help identify African American men with early, localized prostate cancer who are most likely to harbor more aggressive disease.

Key Points: 
  • (Nasdaq: VCYT) announced that data published today in the Journal of the National Cancer Institute demonstrate that the companys Decipher Prostate Genomic Classifier may help identify African American men with early, localized prostate cancer who are most likely to harbor more aggressive disease.
  • The integration of the Decipher classifier with traditional clinical risk factors was shown to improve identification of the subset of African American men with more aggressive disease.
  • The VANDAAM trial enrolled men with low- or intermediate-risk prostate cancer as classified by the National Comprehensive Cancer Network (NCCN) Guidelines for Prostate Cancer.
  • For the current analysis, researchers identified a clinically balanced cohort of 226 men (113 African American men and 113 non-African American men) from the study and performed genomic analysis using the Decipher Prostate classifier to generate Decipher risk scores.

TAE Life Sciences Sponsored Study Details Results of Proton Boron Fusion Therapy Biological Effectiveness

Retrieved on: 
Thursday, September 22, 2022

Proton Boron Capture Therapy (PBCT) is a novel approach of particle therapy aimed at enhancing proton biological effectiveness by exploiting the fusion reaction between low-energy protons and a boron drug to destroy cancer cells via radiation delivery.

Key Points: 
  • Proton Boron Capture Therapy (PBCT) is a novel approach of particle therapy aimed at enhancing proton biological effectiveness by exploiting the fusion reaction between low-energy protons and a boron drug to destroy cancer cells via radiation delivery.
  • TAE Life Sciences and the Department of Radiation Physics at The University of Texas MD Anderson Cancer Center conducted a study, Effect of boron compounds on the biological effectiveness of proton therapy , to identify whether PBCT will produce an increased biological effect in destroying the tumor.
  • "TAE Life Sciences is proud of this proton boron fusion study, said Bruce Bauer, PhD, CEO of TAE Life Sciences.
  • TAE Life Sciences (TLS) is a privately held biotechnology company committed to developing a new biologically targeted radiation therapy based on Boron Neutron Capture Therapy (BNCT).

Guerbet: 2022 half-year results

Retrieved on: 
Wednesday, September 21, 2022

The 2022 half-year financial statements, approved by the Board of Directors on Wednesday, September 21, 2022, underwent a limited review by the statutory auditors.

Key Points: 
  • The 2022 half-year financial statements, approved by the Board of Directors on Wednesday, September 21, 2022, underwent a limited review by the statutory auditors.
  • This discipline enabled it to limit the impact of rising costs of raw materials and other supplies (iodine in particular).
  • As of June 30, 2022, equity totaled 429million, compared with 405million on Friday, December 31, 2021.
  • This did not prevent a further improvement in the debt ratio, with a net debt/equity ratio of 0.59 as of June 30, 2022, compared with 0.64 a year earlier.